> 数据图表请问一下海外CXO企业年报复盘2025-7-1海外CXO企业年报复盘类型公司关键指标2023年报所示2024一季报所修改 2024半年报所修改2024三季报所修2024业绩 趋势备注改2024FY业绩指引药物发现及临床前CROCRL收入增速1.0% – 4.0%1.0% – 4.0%(4.5)% – (2.5)%(3.0)%-(2.0)%(1.9)%↓↑↑全球pharma和biotech销售额全年均下降，但biotech收入在24Q4自23Q3以来首次恢复增长。DSA量级齐降。GAAP EPS/$7.90 – 8.407.60 – 8.105.65 – 5.955.30 - 5.500.20↓↓↓生物制剂和CDMO商誉减值16CDMOLonzaCER sales growthFlatCORE EBITDA marginin high twenties收入/$M （增速）IQVIAAdjusted EBITDA/$M（增速）Adjusted EPS/$ （增速）收入/$M （增速）MEDPACEEBITDA/$M （增速）临床CRONet Income/$M （增速）收入/$M （增速）Adjusted EPS/$ （增速）收入/$B （增速）Adjusted EPS/$ （增速）ICONLabcorp资料来源：公司公告，华安证券研究所15400-15650 (2.8%-4.4%)3700-3800 (3.7%-6.5%)10.95-11.25 (7.4%-10.3%)2150-2200 (14.0%-16.7)400.0-430.0 (10.3%-18.6%)326.0-348.0 (15.3%-23.1%)8400-8800(3.4%-8.4%)14.50-15.30 (13.4%-19.6)12.8-13.0(4.7%-6.5%)14.30-15.40(5.5%-13.6%)Flatin high twenties(27–29%)15425-15525 (2.9%-3.6%)3705-3765 (3.8%-5.5%)11.10-11.30(8.8%-10.8%)2125-217515350-15400 (2.4%-2.8%)3675-3700 (2.9%-3.7%)11.10-11.20 (8.8%-9.8%)2090-213015325-15575 (2.3%-3.9%)3700-3800 (3.7%-6.5%)10.95-11.25 (7.4%-10.3%)2150-2200(14.0%-16.7%)(12.7%-15.3%)(10.8%-12.9%)415.0-445.0 (14.5%-22.8%)430.0-460.0 (18.6%-26.9%)450.0-470.0(24.1%-29.7%)347.0-369.0361.0-383.0376.0-388.0(22.7%-30.5%)(27.7%-35.4%)(33.0%-37.2%)8480-8720 (4.4%-7.4%)14.65-15.15 (14.5%-18.5%)12.8-13.0(4.8%-6.4%)14.45-15.35 (6.6%-13.2%)8450-8550 (4.1%-5.3%)15.00-15.20 (17.3%-18.8%)13.0-13.1(6.4%-7.5%)14.30-14.90 (5.5%-9.9%)8260-8300(1.7%-2.2%)13.90-14.10 (8.7%-10.2%)13.0-13.1(6.6%-7.3%)14.30-14.70 (5.5%-8.4%)-0.2%↓24年新客户数量和项目数量创新高；29%持平CGT早期业务复苏商业化批次成功率高达99%；154052.8%36843.2%11.139.1%2109.111.8%480.232.5%404.443.0%82822.0%14.009.5%13.017.0%14.577.4%↓↓↑ • 因重大试验推迟下调全年预期，• Q3末在手订单创新高• 《IRA》影响客户决策推迟、可支配支↓持平出减少、重新梳理管线↑↓持平• 2024订单取消量新高（金额+50%）• 竞争激烈，定价有影响↓↓持平2024订单取消量创新高↑↑↑↑↑↑↓↓持平↓↓持平↑持平对未来几个季度生物技术领域的复苏持谨慎态度↓↓持平受Invitae的收购影响华安证券综合其他
